Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-270-3631
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30,000.00
Profitability
Miscellaneous
Employees50
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
8 analysts have issued 12-month price targets for Clearside Biomedical's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate Clearside Biomedical's share price to reach $4.1667 in the next year. This suggests a possible upside of 230.7% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.
What is the consensus analysts' recommendation for Clearside Biomedical?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clearside Biomedical.
What are Wall Street analysts saying about Clearside Biomedical stock?
Here are some recent quotes from research analysts about Clearside Biomedical stock:
- 1. According to Zacks Investment Research, "Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. " (8/12/2019)
- 2. Wedbush analysts commented, "Our $69 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate of $7.49 to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development." (8/6/2019)
Has Clearside Biomedical been receiving favorable news coverage?
Press coverage about CLSD stock has been trending positive this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clearside Biomedical earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Clearside Biomedical.
Are investors shorting Clearside Biomedical?
Clearside Biomedical saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,732,100 shares, a drop of 23.4% from the June 30th total of 2,262,300 shares. Based on an average daily volume of 369,700 shares, the short-interest ratio is presently 4.7 days. Approximately 7.1% of the company's stock are sold short. View Clearside Biomedical's Current Options Chain.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include TAIWAN LIPOSOME/S (TLC), Nature's Sunshine Products (NATR), Adamas Pharmaceuticals (ADMS), Affimed (AFMD), Applied Therapeutics (APLT), Cerecor (CERC), Newron Pharmaceuticals (NWPHF), LifeVantage (LFVN), Poxel (PXXLF), REDHILL BIOPHAR/S (RDHL), Sol Gel Technologies (SLGL), Mustang Bio (MBIO), Hookipa Pharma (HOOK), Osmotica Pharmaceuticals (OSMT) and XOMA (XOMA).
What other stocks do shareholders of Clearside Biomedical own?
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
- Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
- Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
- Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
- Mr. Rick McElheny, VP of Corp. Devel.
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?
Clearside Biomedical's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.46%), BlackRock Inc. (1.53%), Northern Trust Corp (0.79%), GSA Capital Partners LLP (0.34%), Paloma Partners Management Co (0.33%) and Jane Street Group LLC (0.27%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, Daniel H White and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical.
Which institutional investors are selling Clearside Biomedical stock?
Which institutional investors are buying Clearside Biomedical stock?
CLSD stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Paloma Partners Management Co, Jane Street Group LLC and A.R.T. Advisors LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $1.26.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $47.58 million and generates $30,000.00 in revenue each year. The company earns $-82,820,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.View Additional Information About Clearside Biomedical.
What is Clearside Biomedical's official website?
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
